With a shortage of school nurses, the hope is that the technology can be harnessed to get kids seen more quickly when they need it.
Vaccine stocks mostly fell Friday after the CDC authorized Moderna, J&J boosters, plus a mix-and-match strategy for Covid booster shots.
Shares of 23andMe Holding (NASDAQ: ME) stock slipped in Friday morning trading after the genetic data miner announced that it will spend $400 million to acquire on-demand online medical care and pharmacy services platform Lemonaid Health (not to be confused with Lemonade (NYSE: LMND), the insurance provider). As of 11 a.m. EDT, 23andMe shares are down 4.2%. 23andMe noted that bringing Lemonaid Health's "innovative telemedicine and prescription drug delivery services" onboard could be "an important step in transforming the traditional primary care experience and making personalized healthcare a reality."
Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence. The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-527, badly missed the mark in a phase 2 trial called MOONSONG for patients with mild or moderate cases of COVID-19. AT-527 is being co-developed with pharma heavyweight Roche (OTC: RHHBY).
Shares of Ionis Pharmaceuticals (NASDAQ: IONS), a biotechnology company, have fallen around 13.6% since their closing price on Friday, Oct. 15, 2021. Investors were disappointed by phase 3 clinical trial results for tofersen, an experimental treatment for amyotrophic lateral sclerosis. Treatment with tofersen was supposed to help reduce physical symptoms of ALS, a progressive neurodegenerative disorder that affects around 20,000 new U.S. patients annually.
Leen Kawas resigned from her post as Athira CEO after an investigation found she manipulated data in papers — and ATHA stock soared.
Right now, investors are waiting for news from BeyondSpring (NASDAQ: BYSI), Allakos (NASDAQ: ALLK), and Deciphera Pharmaceuticals (NASDAQ: DCPH) that could send their stock prices screaming higher, or lower, overnight. Shares of BeyondSpring more than tripled in August after the clinical-stage biotech's lead candidate, plinabulin, produced positive results. During a clinical trial with lung cancer patients called Dublin-3, adding plinabulin to standard chemotherapy significantly reduced patients' risk of death.
"Things started to go south for me was when I hit, I think it was 25."View Entire Post ›
On Tuesday, Johnson & Johnson (NYSE: JNJ) exceeded Wall Street's profit expectations but revenue missed forecasts for its third quarter. However, this report has been overshadowed by criticism about its handling of the opioid crisis and the development of a comparatively less effective Covid vaccine under outgoing CEO Alex Gorsky. Third Quarter Figures The pharma giant sold $502 million of its Covid-19 vaccine over the quarter, bringing in revenue of $23.34 billion that came below the expected $
Ali Parsa, Babylon Founder and CEO, joins Yahoo Finance Live to discuss the company’s rapid growth and the future of digital health care.
Shares of vaccine maker Moderna hit highs of nearly $500 earlier this year. No doubt, Moderna has been an exceptional investment over the past year, soaring 350% while the S&P 500 has risen by just 29%. Two stocks I'd buy instead of Moderna are AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK).
(Bloomberg) -- People across the U.S. have been advised to throw away all unlabeled red, white and yellow onions after a mass salmonella outbreak sickened hundreds of people across 37 states.Most Read from BloombergForget Palm Springs—Santa Fe Is the New Mecca for Modern ArchitectureGoogle’s Biggest Moonshot Is Its Search for a Carbon-Free FutureA $30 Billion Fortune Is Hiding in China’s Silicon ValleyBeef Industry Tries to Erase Its Emissions With Fuzzy Methane MathGoogle’s CEO: ‘We’re Losing T
The FDA approval comes as Genentech and parent Roche face generic competition for Lucentis and other companies pursue longer-acting drugs for wet AMD patients.
The next donnybrook in Alzheimer's disease is looming. Biogen gained the first approval, and a slew of biotech stocks are now lining up.
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas Resigns Athira Pharma, Inc. (NASDAQ: ATHA) announced the appointment of Mark Litton, who was serving as the company's chief operating officer, as its chief executive officer. Litton succeeds Leen Kawas, who has resigned from her position as President and CEO and as a member of the company's board. Kawas was placed on leave af
Some CEOs worry they'll lose workers they can't replace if they require all employees to get vaccinated.
The mother of two also claims that the milk helps her fiancé's health—but is that entirely true? Here's what the science says.
In a White House COVID-19 response team briefing on Friday, Centers for Disease Control and Prevention Director Rochelle Walensky walked through the latest guidance on booster shots for all three of the approved COVID-19 vaccines.
Two ER nurses in Marietta, Georgia, became inseparable during the pandemic. A proposal was imminent, and one of the nurses’ devotion to her patients provided the perfect set-up. Norah O'Donnell has more.
After months of debating the need for booster shots, the U.S. Food and Drug Administration (FDA) has authorized an additional dose for select recipients of the Pfizer and Moderna vaccines and all of those who initially got Johnson&Johnson's one-dose vaccine. While Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky, MD, still has to sign off on her agency's official recommendations for Moderna and Johnson&Johnson booster doses, millions of eligible recipients are already
MAPLEWOOD, N.J. — A 7-year-old girl came home from school earlier this month upset, impatient to tell her mother a story. The second grader said her teacher in Maplewood had begun to pull off a hijab she wears as an observant Muslim, exposing her hair and prompting her to hold on to the head covering, the family’s lawyer said. The girl’s mother recounted the story on Facebook. Then, an Olympic medalist who fences in a hijab and lives in the same New Jersey school district denounced the incident